IDEAYA Biosciences announced the promotion of Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective September 28, 2026. White has served as Chief Scientific Officer at the precision medicine oncology company since 2021, a five-year tenure during which Chief Executive Officer Yujiro S. Hata credited him as a key driver of IDEAYA's research and development innovation. Before joining IDEAYA, White was Chief Scientific Officer and Head of Tumor Biology at Pfizer, where he led cross-disciplinary groups building an oncology small-molecule clinical pipeline focused on first-in-class therapies. He previously spent more than twenty years in academia at UT Southwestern as a Professor of Cell Biology and founding Director of the Cancer Intervention and Prevention Discovery Program, and in 2015 received the inaugural Outstanding Investigator's Award from the National Cancer Institute. White holds a Ph.D. in Biology from the University of North Carolina at Chapel Hill and completed postdoctoral research at Cold Spring Harbor Laboratories in New York.
Ideaya Biosciences IncIDEAYA promotes its Chief Scientific Officer to President, R&D, a leadership change tied to its R&D innovation.
Pfizer Inc
